dc.contributor.author |
Weisel, Katja |
|
dc.date.accessioned |
2016-03-18T11:10:03Z |
|
dc.date.available |
2016-03-18T11:10:03Z |
|
dc.date.issued |
2015 |
|
dc.identifier.issn |
0887-6924 |
|
dc.identifier.uri |
http://hdl.handle.net/10900/68881 |
|
dc.language.iso |
en |
de_DE |
dc.publisher |
Nature Publishing Group |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.1038/leu.2015.80 |
de_DE |
dc.rights |
info:eu-repo/semantics/closedAccess |
|
dc.subject.ddc |
610 |
de_DE |
dc.title |
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20151209042647_01000 |
|
utue.publikation.seiten |
1721-1729 |
de_DE |
utue.personen.roh |
Mai, E. K. |
|
utue.personen.roh |
Bertsch, U. |
|
utue.personen.roh |
Duerig, J. |
|
utue.personen.roh |
Kunz, C. |
|
utue.personen.roh |
Haenel, M. |
|
utue.personen.roh |
Blau, I. W. |
|
utue.personen.roh |
Munder, M. |
|
utue.personen.roh |
Jauch, A. |
|
utue.personen.roh |
Schurich, B. |
|
utue.personen.roh |
Hielscher, T. |
|
utue.personen.roh |
Merz, M. |
|
utue.personen.roh |
Huegle-Doerr, B. |
|
utue.personen.roh |
Seckinger, A. |
|
utue.personen.roh |
Hose, D. |
|
utue.personen.roh |
Hillengass, J. |
|
utue.personen.roh |
Raab, M. S. |
|
utue.personen.roh |
Neben, K. |
|
utue.personen.roh |
Lindemann, H-W |
|
utue.personen.roh |
Zeis, M. |
|
utue.personen.roh |
Gerecke, C. |
|
utue.personen.roh |
Schmidt-Wolf, I. G. H. |
|
utue.personen.roh |
Weisel, K. |
|
utue.personen.roh |
Scheid, C. |
|
utue.personen.roh |
Salwender, H. |
|
utue.personen.roh |
Goldschmidt, H. |
|
dcterms.isPartOf.ZSTitelID |
Leukemia |
de_DE |
dcterms.isPartOf.ZS-Issue |
8 |
de_DE |
dcterms.isPartOf.ZS-Volume |
29 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |